BREAST CANCER

Imlunestrant shows significant progression-free survival benefits in advanced breast cancer, offering a promising treatment option for patients.

Giredestrant combined with everolimus significantly improves progression-free survival in advanced ER+, HER2-negative breast cancer after CDK4/6 inhibitors.

Gedatolisib combined with fulvestrant shows significant progression-free survival benefits in advanced breast cancer, regardless of prior treatment duration.

Long-term PALLAS study results reveal no survival advantage for palbociclib plus endocrine therapy over endocrine therapy alone in breast cancer patients.

New research reveals hormone replacement therapy may lower breast cancer risk in BRCA carriers, challenging existing medical guidelines on HRT use.

Elacestrant shows promising results in combination therapies for ER-positive, HER2-negative metastatic breast cancer, enhancing progression-free survival and maintaining safety.

A safety analysis reveals that sacituzumab govitecan and pembrolizumab combination therapy shows manageable side effects in treating metastatic triple-negative breast cancer.

A novel ctDNA assay identifies high-risk triple-negative breast cancer patients post-surgery, highlighting its potential as a crucial prognostic tool.

Alpelisib plus fulvestrant significantly improves progression-free survival in advanced breast cancer patients previously treated with CDK4/6 inhibitors.

Circulating tumor DNA analysis offers a minimally invasive method for detecting key genetic alterations in hormone receptor-positive breast cancer patients.

New research shows less invasive surgical options for breast cancer staging are as effective as traditional methods, enhancing patient quality of life.

New research reveals that preoperative breast MRI does not enhance outcomes for early-stage breast cancer patients, challenging its routine use in treatment plans.

New trial data reveals that combining preoperative radiation with pembrolizumab enhances immune response in high-risk, early-stage breast cancer patients.

Abemaciclib shows promise as a monotherapy for HR-positive, HER2-negative breast cancer after CDK4/6 inhibitor failure, benefiting 33% of patients.

Sacituzumab govitecan enhances quality of life for untreated advanced TNBC patients, despite increased gastrointestinal toxicities compared to chemotherapy.

Subgroup analyses reveal T-DXd significantly improves invasive disease-free survival in early-stage HER2-positive breast cancer compared to T-DM1, regardless of HER2 expression.

Tucatinib enhances frontline maintenance therapy for HER2-positive metastatic breast cancer, significantly improving progression-free survival compared to placebo.

An innovative AI model enhances breast cancer recurrence predictions, outperforming traditional methods and offering tailored treatment insights for patients.

Patients in the DESTINY-Breast09 trial report improved quality of life with T-DXd plus pertuzumab, highlighting distinct side effect profiles compared to standard care.

Giredestrant shows significant improvement in invasive disease-free survival for early breast cancer patients, outperforming standard endocrine therapy in a pivotal trial.

Aromatase inhibitors enhance disease-free survival in HR+/HER2+ early breast cancer, outperforming SERMs without compromising overall survival, according to ALTTO trial findings.

Discover the most anticipated breast cancer abstracts at the 2025 San Antonio Symposium, featuring groundbreaking studies in HR+, HER2+, and TNBC.

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and TNBC. Vote now!

A novel treatment shows promise for leptomeningeal disease in breast cancer, offering hope with improved survival rates and symptom relief.